Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B

Completed · Phase 2 · Has a placebo group

Conditions studied: Chronic Hepatitis B

In brief

The primary objectives of this study are to evaluate the safety, tolerability and antiviral activity of selgantolimod (formerly GS-9688) in virally suppressed chronic hepatitis B (CHB) adults on oral antiviral (OAV) agents.

Key facts

Study ID

NCT03491553

Run by

Gilead Sciences

People needed

48

Starts

2018-04-06

Expected to finish

2020-08-10

Last updated by the study team

2021-08-19

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Maryland, Institute of Human Virology — Baltimore, Maryland, United States
• Auckland Clinical Studies Limited — Auckland, New Zealand

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.